Displaying drugs 13976 - 14000 of 14949 in total
Anti-SARS-CoV-2 equine immunoglobulin fragments
Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19). INOSARS is composed of F(ab’)2 fragments extracted from hyperimmune equine serum.
Investigational
Matched Description: … INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and …
Polyvalent antigen-KLH conjugate vaccine
Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH). It is under investigation in clinical trial NCT01223235 (Polyvalent Vaccine-klh Conjugate + Opt-821 Given in Combination With Bevacizumab).
Investigational
Matched Description: … vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and …
Hymenialdisine
Experimental
N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
Experimental
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
IGN301
IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
Investigational
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
HSV-2 theracine
HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Investigational
Q-Derp1
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
TRX1
TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
Investigational
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Gavilimomab
Investigational
Crypthecodinium cohnii DHA oil
Experimental
Liquidambar styraciflua resin
Experimental
Insulin argine
Experimental
Placulumab
Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
Glucagon-like peptide II
Glucagon-like peptide II is under investigation for the basic science of Short Bowel Syndrome.
Investigational
Denenicokin
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Investigational
Displaying drugs 13976 - 14000 of 14949 in total